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ABSTRACT
Objective: To provide an overview of the pathophysiology of thyroid diseases 
in pregnancy and the various treatment methods currently available in its 
management. 
Data source: Review of literature was affected through index medicus search of major 
published journals and books. 
Data selection: Published data on thyroid diseases on women in the reproductive age 
group over the last four decades were utilised.
Data extraction: Abstracts and full text of selected manuscripts were read and analysed 
to determine their contribution to this article. 
Data synthesis: All relevant articles were reviewed and contributions extracted. 
Conclusion: Thyroid diseases are the second most common endocrinopathies in 
pregnancy. Numerous hormonal changes and metabolic demands occur in pregnancy 
resulting in complex changes in maternal thyroid function. Thyroid diseases involves 
a multidisciplinary team approach to achieve good metabolic control and excellent 
obstetric care in order to ensure normal maternal and perinatal outcome. 
INTRODUCTION
Thyroid disorders are the second most common 
endocrinopathies found in pregnancy (1). Significant 
thyroid disease complicates about 0.8% of all 
pregnancies approximately 0.2% hyperthyroid and 
0.6% hypothyroid (2). Disease of the thyroid are 
generally much more prevalent in females than in 
the males and with marked preference for women 
in the reproductive age group, of which 5 - 15% may 
be affected (3). The prevalence of thyroid disease 
in pregnancy is however less than expected for the 
age-related population because thyroid diseases 
significantly affect fertility rate and autoimmune 
thyroid disease tend to remit during pregnancy 
(2,4).
 Numerous hormonal changes and metabolic 
demands occur in pregnancy, resulting in complex 
changes in maternal thyroid function, yet normal 
pregnancy is considered to be a euthyroid state 
(5). Pregnancy itself does not cause abnormal 
thyroid function, but rather, hypothyroidism and 
hyperthyroidism may be found in pregnant and 
non-pregnant women alike. 
Thyroid gland changes in pregnancy: The thyroid gland 
enlarges in pregnancy due to increased vascularity 
and cellular hyperplasia. Maternal thyroid function 
is modulated by three independent but interrelated 
factors (5).
(i) An increase in thyroxin-binding globulin (TBG) 
during the first trimester, resulting in increased 
binding of thyroxin. 
(ii) An increase in HCG (TRH-like activity) 
concentration that stimulate the thyroid 
gland. 
(iii) Significant increase in urinary iodine excretion 
resulting in a fall in plasma iodine concentration 
and; 
In the aggregate, these factors may be responsible 
for the increased thyroid demand or thyroid 
‘strain’ observed during pregnancy. The end result 
is a relatively elevated thyroid hormone in early 
pregnancy and this may be necessary for normal 
foetal development, especially or the foetal nervous 
system (6). 
Pregnancy in sub-clinical hypothyroid disorders: 
Hypothyroidism in pregnancy is rare while sub clinical 
hypothyroidism is more commonly encountered (7). 
The clinical diagnosis of sub clinical hypothyroidism 
is based on the chemical analysis indicating a normal 
free thyroxin level und a slightly elevated thyrotrophic 
level. The aetiologies of hypothyroidism include 
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iodine deficiency, autoimmune thyroiditis, post 
thyroid ablation therapy and post thyroidectomy. 
 The spectrum of women with overt or sub 
clinical hypothyroid in pregnancy include women 
who discontinue thyroid hormone therapy, those 
on therapy requiring larger doses, hyperthyroid 
patients on excessive amount of antithyroid drugs 
and some patients on lithium or amiodarone therapy 
(9,10). Patients with sub clinical disease are usually 
asymptomatic and may get pregnant and when they 
do, the symptoms of mild hypothyroidism mimic 
those of normal pregnancy, making diagnosis difficult. 
These symptoms include lethargy, constipation, 
weight gain, muscle cramping, carpel tunnel 
syndrome, dry skin and hair and a deeper voice. 
 Maternal  morbidi ty  associated with 
hypothyroidism includes microcytic anaemia 
pre eclampsia, placental abruption, post partum 
haemorrhage, cardiac dysfunction and pregnancy 
wastage. Foetal or neonatal complications 
include prematurely, low birth weight, congenital 
anomalies, stillbirths and poor neuropsychological 
development (1).
 Maternal replacement therapy and close 
monitoring is indicated in sub-clinical disease to 
normalise maternal thyrotrophin levels. When the 
foetal thyroid is normal and there is no deficiency, 
maternal hypothyroidism may not adversely affect 
subsequent mental development of the offspring (10). 
With only mild elevation of TSH as seen in sub clinical 
hypothyroidism, the foetus is at less risk from mild 
maternal thyroid failure and TSH does not cross the 
placenta. 
The effects of thyroid disease on the foetus: Studies in 
the last two decades have shown an important role 
of maternal thyroid hormones in embryogenesis 
(11). The foetal thyroid only begins to produce 
significant amount of thyroid hormones by 18 to 
2 weeks gestation. Prior to that time, the foetus is 
completely dependent upon transplacental transfer 
of maternal thyroid hormones. Adverse effect on the 
intellectual development may occur in children of 
mothers with mild thyroid deficiency in the first 20 
weeks of gestation (12). 
 Foetal  complications   of  maternal 
hyperthyroidism include spontaneous abortion, 
premature labour, stillbirths, low birth weight 
and foetal/neonatal hyperthyroidism. Foetal 
thyrotoxicosis may result from transplacental thyroid 
stimulating antibodies, giving rise to widespread 
foetal autoimmune reaction with lymphatic 
hypertrophy, thrombocytopenia, foetal goiter and 
exophthalmos (14).
 Foetal or neonatal hypothyroidism may 
follow maternal administered thioamides which 
block thyroid hormone biosynthesis in the foetus. 
Transplacental passage of maternal thyrotropin-
receptor blocking antibodies may cause foetal 
hypothyroidism in women with autoimmune thyroid 
diseases. Maternal iodine deficiency also results in 
foetal/neonatal hypothyroidism with or without 
goiter in the foetus (star gazing foetus). Other foetal 
complications of maternal hypothyroidism include 
spontaneous abortion, low birth weight, foetal death 
and lower intelligent Quotient (13). Treatments 
include maternal thyroxine therapy as well as use of 
intraamniotic thyroxine injection. In mothers being 
managed on antithyroid medication, the smallest 
dose that maintains maternal free hormones and TSH 
within the normal range should be used in order to 
avoid foetal hypothyroidism. 
Post-partum thyroiditis: This condition presents as 
hypothyroidism (40%), hyperthyroidism (30%) or 
hyperthyroidism followed by hypothyroidism (12). 
It’s a transient autoimmune thyroidities found in 5-
10% of women during the first year after childbirth 
(15). The propensity for thyroiditis antedates 
pregnancy and is directly related to the increasing 
level of thyroid auto antibodies. Thyroid biopsy 
shows lymphocytic thyroiditis. Risk factors include 
previous thyroid dysfunction, hereditary thyroid 
or other autoimmune diseases and type 1 diabetes 
mellitus (16). 
 Two clinical phases of post partum thyroiditis 
are known (4). In the first four months post delivery, 
transient destruction-induced thyrotoxicosis from 
excessive release of hormones from glandular 
disruption occurs in about 4% of women. It is of 
abrupt onset and is characterised by small painless 
goiter, fatigue and palpitation. Antithyroid drugs 
are ineffective but Beta adrenergic-blockers may be 
given. Two-third of patients return to euthyroid state 
while the remaining develops transient or permanent 
hypothyroidism. 
 Between four to eight months post partum 2-5% 
of women develop hypothyroidism groin thyroiditis. 
A third of these would have gone through the 
thyrotoxicosis phase. Thyroxine replacement may be 
given for 6-12 months, but some may have developed 
permanent hypothyroidism. 
 In clinical practice however, thyroiditis is 
infrequently diagnosed because it typically develops 
months after delivery and has nonspecific symptoms 
such as depression and memory impairment which 
are easily attributed to other causes. 
Effects of antithyroid drugs in pregnancy: Antithyroid 
drug regimen is the appropriate treatment for 
most women with hyperthyroidism in pregnancy. 
Radioactive iodine is contraindicated in pregnancy 
while surgery is reserved for those with significant 
drug intolerance or extremely poor compliance. 
 The standard therapy for hyperthyroidism is the 
use of antithyroid drugs with the aim of reducing the 
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circulating free T4 concentration into the high normal 
or just elevated range. Close monitoring with frequent 
measurement of TSH and T4 must be carried out twice 
weekly at the beginning of treatment and every 2-4 
weeks when euthyroidism is achieved (7).
 The commonly used antithyroid drugs are 
propylthiouracil and methimazole; both are thiamine 
drugs which act by blocking hormone synthesis at 
the start of organification and iodotyrosine coupling. 
Both drugs are effective in controlling symptoms and 
no one is superior to the other in terms of efficacy, (17) 
though aplasia cutis was reported in association with 
methimazole (18).  Side effects of antithyroid drugs 
occur in 3-5% treated patients (19). The most common 
complications of both drugs are pruritus and skin 
rash. Other less common complications are migratory 
polyarthritis, a lupus like syndrome and cholestatic 
jaundice. Agranulocytosis is a serious but unusual 
complication which necessitates discontinuation of the 
drugs. Of clinical significance is the effect of antithyroid 
drugs on the foetus. Excessive amount of antithyroid 
drugs are associated with foetal hypothyroidism and 
goitre. Because of the unpredictable transplacental 
passage of thyroid hormone, supplementation with 
either T3 or T4 provides a false sense of security, making 
the mother euthyroid while continuing foetal exposure 
to high doses of antithyroid drugs than would be 
necessary without thyroid hormone supplementation. 
Use of adjunctive therapy with staple iodine is also not 
justified in pregnancy because it crosses the placenta 
easily and may be responsible for development of 
large foetal goitre, hypothyroidism and foetal death 
(20). Patients with small goiters or short duration of 
symptoms and those on minimal amount of antithyroid 
medication may be able to discontinue antithyroid 
medications by 34 weeks and beyond (7). 
 Propanolol and other adrenergic-blocking drugs 
have been associated with placental insufficiency, 
intrauterine growth (21) retardation, excessive 
uterine irritability and foetal bradycardia. Their 
use should therefore be restricted to severe cases of 
hyperthyroidism. 
Thyroid storm in pregnancy: Thyroid storm is a life-
threatening condition with clinical diagnosis based 
on severe signs of thyrotoxisis; it is characterised by 
significant hyperpyrexia (103°F), neuropsychiatry’s 
symptoms, nausea and vomiting. It is rare in 
pregnancy but could be precipitated by delivery, 
acute illness, infection or surgery (22). It requires early 
recognition and aggressive therapy in an intensive 
care unit. Management includes supportive therapy 
with fluids, correction of electrolyte abnormalities, 
oxygen therapy as needed and control of hyperpyrexia 
with acetaminophen. Antibiotics could also be given 
in case of infection. 
 Beta-blockers which acts by suppressing 
adrenergic output and block peripheral conversion 
of T4 to T3 are also useful. It is given as 60-80mg 
every 4 four hours orally or 1mg/min intravenously. 
Methimazole 30mg or propylthiouracil 300mg every 
6 hours is given orally or via NG tube. They block 
the synthesis of thyroid hormone in a few hours. One 
hour after the administration of thioamides, iodine is 
administered in form of lugol’s solution, 10 drops 8 
hourly or if available, sodium iodide 1g intravenously 
every 12 hours. Intravenous dexamethazole 2mg 6 
hourly for 4 doses also help to further block peripheral 
conversion T4 to T3.
Pregnancy post-thyroidectomy: Different clinical 
situations may be met when counselling women 
with current or past thyroid diseases contemplating 
pregnancy. Hyperthyroid women under treatment 
may be taking antithyroid drug therapy and the 
potential side effects of antithyroid drugs on the foetus 
should be discussed. Those who have had radioactive 
ablation need to wait six months after the therapeutic 
dose is administered before contemplating pregnancy 
while those who had had surgery still needs to 
be euthyroid at the time of conception. Previous 
ablation treatment for Grave’s disease or thyroid 
carcinoma requires adjustment in the dose of thyroid 
replacement therapy soon after conception (23) and 
the risk of foetal hyperthyroidism despite maternal 
euthyroidism still exist in mothers with high titres 
of TSI following ablative therapy.
CONCLUSION
Thyroid disorders in pregnancy can be adequately 
tackled with multidisciplinary team approach for 
successful outcomes as it’s with diabetes mellitus 
today. It is imperative to advise women with chronic 
thyroid diseases to plan their pregnancies and contact 
their health care professional as soon as the diagnosis 
of pregnancy is made. Good metabolic control coupled 
with excellent obstetric care can ensure normal 
maternal and perinatal outcome. 
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